Candriam SCA’s 10x Genomics TXG Stock Holding History

Candriam SCA’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-14,000	Closed	-$399K	–	890
2022 Q3	$399K	Sell	14,000 -10,000	-42%	-$381K	﹤0.01%	841
2022 Q2	$1.09M	Buy	24,000 +18,818	+363%	+$976K	0.01%	613
2022 Q1	$394K	Buy	5,182 +848	+20%	+$74.2K	﹤0.01%	755
2021 Q4	$646K	Hold	4,334	–	–	﹤0.01%	728
2021 Q3	$631K	Buy	4,334 +658	+18%	+$113K	﹤0.01%	768
2021 Q2	$720K	Buy	+3,676	New	+$665K	﹤0.01%	770

Other funds holding TXG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SIM

SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Candriam SCA's TXG Position: Q4 2022 in Review

Candriam SCA sold out of 10x Genomics (TXG) in Q4 2022, closing a stake of 14,000 shares — an estimated $399K sold.

Candriam SCA first reported a position in TXG in Q2 2021 and held it in 6 quarters. The position peaked at $1.09M in Q2 2022. 268 funds tracked by Wall St. Rank hold TXG as of Q4 2022.

Candriam SCA reported no remaining 10x Genomics position as of Q4 2022 after selling out during the quarter.
Candriam SCA sold 14,000 10x Genomics shares in Q4 2022, an estimated $399K.
Candriam SCA first reported a position in 10x Genomics in Q2 2021 and held it in 6 quarters.
Candriam SCA's 10x Genomics position peaked at $1.09M in Q2 2022.
268 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2022.

Based on Candriam SCA's 13F filing for Q4 2022, filed 13 Feb 2023.